Select Page

DO_-_China_8-13The recent events of GlaxcoSmithKline and other pharmaceutical companies operating in China highlight some of the challenges and exposures faced by international companies working in foreign jurisdictions. As events develop, Lockton experts Ray Pallett and Neo Combarro highlight key areas to consider when looking at the terms of D&O global insurance coverage. Read the executive summary discussing

  • Local D&O policies
  • Bribery & Corruption
  • Conduct Exclusion
  • Sanctions Clause